Précisez une action ou une cryptomonnaie dans la barre de recherche pour obtenir un récapitulatif
AlzeCure Pharma
ALZCURAlzeCure Pharma AB (publ), a pharmaceutical company, develops drug therapies for the treatment of severe diseases and conditions that affect the central nervous system. The company is involved in the development of drug candidates based on the NeuroRestore, Alzstatin, and Painless research platforms. Its products pipeline includes ACD856 for the treatment of Alzheimer's disease, sleep disorders, depression, traumatic brain injuries, and Parkinson's disease, which is in phase I clinical trial; ACD857, ACD679, and ACD680 that are in preclinical trial for the treatment of Alzheimer's disease; ACD440, a TRPV1 antagonist that has completed phase I clinical trial for neuropathic pain indications; and ACD137, negative allosteric modulator (NAM) of TrkA receptors for osteoarthritic pain indications. AlzeCure Pharma AB (publ) was founded in 2012 and is based in Huddinge, Sweden. Address: HAelsovAegen 7, Huddinge, Sweden, 141 57
Analytics
Objectif de Cours de WallStreet
107.53 SEKRatio C/B
–Rendement du dividende
–Année actuelle
L'année dernière
Trimestre en cours
Le dernier trimestre
Année actuelle
L'année dernière
Trimestre en cours
Le dernier trimestre
Chiffres clés ALZCUR
Analyse des dividendes ALZCUR
Croissance des dividendes sur 5 ans
–Croissance continue
–Ratio de distribution Moyenne sur 5 ans
–Historique des dividendes ALZCUR
Valorisation des titres ALZCUR
financières ALZCUR
Résultats | 2019 | Dynamique |